论文部分内容阅读
目的:探讨“三阴性”乳腺癌Ki-67表达对新辅助化疗疗效的预测价值,有助于乳腺癌治疗的选择及预后。方法:对74例分别实施TEC及CEF方案新辅助化疗的“三阴性”乳腺癌病例进行回顾性分析,应用免疫组化法检测化疗前后Ki-67表达,分析Ki-67表达与疗效关系。结果:Ki-67高表达患者接受CET新辅助化疗化疗PCR率更高。结论:Ki-67的高表达可以作为“三阴性”乳腺癌CET方案化疗疗效预测指标。
Objective: To investigate the predictive value of Ki-67 expression in neoadjuvant chemotherapy for “triple negative” breast cancer, which is helpful for the selection and prognosis of breast cancer. Methods: A retrospective analysis was performed on 74 cases of “triple negative” breast cancer treated with neoadjuvant chemotherapy with TEC and CEF respectively. The expression of Ki-67 was detected by immunohistochemistry before and after chemotherapy. The relationship between the expression of Ki-67 and the curative effect was analyzed . Results: The patients with high expression of Ki-67 had higher rates of PCR for neoadjuvant chemotherapy. Conclusion: The high expression of Ki-67 can be used as a predictor of the efficacy of chemotherapy in CET regimen of “triple negative” breast cancer.